Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrypNAC-II: NAC and Tryptophan in Schizophrenia
NCT04013555Phase 2Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2020
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of acetylcysteine in schizophrenia, schizoaffective disorder, schizophreniform disorder, sponsored by University of Maryland, Baltimore. Started Jan 2020; status: completed.
02
Drugs
acetylcysteine
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT04013555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04013555.